House appropriators on Wednesday (May 17) unveiled a draft fiscal 2024 spending bill for FDA with essentially flat discretionary funding that could stifle a number of FDA priorities and hinder pay increases for agency employees and that if signed into law would lead to “explosive” funding discussions in fiscal 2025 because it relies on one-time recissions and clawbacks of unspent pandemic money, according to an FDA funding advocate. The bill would give the agency a total of $6.6 billion in...